Please refer to the full KEYTRUDA Summary of Product Characteristics before prescribing KEYTRUDA.

Click here for GB Prescribing Information and **click here** for NI Prescribing Information.

KEYTRUDA® (pembrolizumab)

YOUR REPORTING OF BIOMARKER STATUS MAY HELP INFORM PERSONALISED PATIENT TREATMENT OF ELIGIBLE PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCERS[1]

KEYTRUDA® (pembrolizumab), in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1.[2]

For advanced cervical cancer:[3]

TEST

PD-L1/ CPS

Test for PD-L1 with IHC 22C3 pharmDx and report expression by CPS as a score between 0 and 100.

IDENTIFY

Identify patients with a PD-L1 expression of CPS ≥1 to help determine potential eligibility for **KEYTRUDA** in combination with chemotherapy ± bevacizumab.

CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1.

References: 1. Iida, Miho et al. Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review). *Molecular and Clinical Oncology.* 2014:2(5);647–655. doi:10.3892/mco.2014.324. **2.** KEYTRUDA Summary of Product Characteristics. **3.** Agilent Technologies, Inc. Instructions for Use: PD-L1 IHC 22C3 pharmDx.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD, UK (Tel: 0208 154 8000)

MSD

GB-PDO-02787. June 2023. Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR. A company registered in England and Wales. Company Registration Number: 233687